LONDON/COPENHAGEN, Oct 17 (Reuters) - Novo Nordisk

has appointed U.S. pharmaceutical executive Greg

Miley as its new head of corporate affairs, according to a

statement he posted on LinkedIn, as the obesity drugmaker faces

growing pressure from the Trump administration on drug pricing.

Miley, an American, is currently senior vice president of

government affairs at U.S. pharmaceutical giant AbbVie ( ABBV ).

He posted the statement on LinkedIn on Friday and Novo Nordisk

shared the statement with Reuters.